Form 4: Kevin Tang Acquires Boundless Bio Shares

Kevin Tang, a director and 10% owner of Boundless Bio, Inc., has acquired a significant number of common shares through various transactions in early July 2026.

Summary

• Kevin Tang, a director and 10% owner of Boundless Bio, Inc., has acquired a total of 57,210 shares of common stock across three transactions between July 6th and July 8th, 2026.
• These acquisitions were made at weighted-average prices ranging from $2.46 to $2.49 per share.
• Following these transactions, Kevin Tang, through various affiliated entities including Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc., beneficially owns a substantial amount of Boundless Bio stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing due to insider buying, but it lacks strategic or financial performance data to warrant a higher score.

Positives

• Director and significant shareholder Kevin Tang has increased his beneficial ownership in Boundless Bio, Inc.
• The acquisitions indicate confidence from a key insider in the company's prospects.

Future Outlook

No specific forward-looking statements or guidance are present in this Form 4 filing, which solely reports on past transactions.

Industry Context

StockSavvy.ai notes that insider purchases, as reported in Form 4 filings, can be a signal of management's confidence in the company's future performance. However, this filing is purely transactional and does not provide strategic insights.

Stakeholder Impact

• Shareholders may view the increased stake by a director and 10% owner as a positive signal of confidence in the company's value.

Key Dates

Keywords

Boundless Bio, Kevin Tang, Form 4, Insider Trading, Common Stock, Beneficial Ownership, SEC Filing, Tang Capital